Worcester HIV Vaccine (WHV) is a biotechnology company dedicated to developing an effective vaccine to prevent HIV infection around the world. Through global partnerships, WHV is developing the most advanced polyvalent DNA-prime/protein-boost vaccine that will provide broad immune protective responses to HIV for global coverage.
WHV works with research institutions, government agencies, biotech companies and others organizations to test the safety and efficacy of its candidate vaccine and is developing and optimizing the biomanufacturing processes that would allow a faster and more effective path to take the polyvalent candidate vaccine to large-scale clinical trials and market introduction.
WHV is committed to science and innovation and believes that any true breakthrough in science will need to challenge the conventional approach.
